<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR21">
 <label>21.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Morse</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Overman</surname>
    <given-names>MJ</given-names>
   </name>
   <name>
    <surname>Hartman</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Khoukaz</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Brutcher</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Lenz</surname>
    <given-names>HJ</given-names>
   </name>
   <name>
    <surname>Atasoy</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Shangguan</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>el-Rayes</surname>
    <given-names>B</given-names>
   </name>
  </person-group>
  <article-title>Safety of Nivolumab plus low-dose Ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal Cancer</article-title>
  <source>Oncologist.</source>
  <year>2019</year>
  <volume>24</volume>
  <issue>11</issue>
  <fpage>1453</fpage>
  <lpage>1461</lpage>
  <pub-id pub-id-type="doi">10.1634/theoncologist.2019-0129</pub-id>
  <?supplied-pmid 31147488?>
  <pub-id pub-id-type="pmid">31147488</pub-id>
 </element-citation>
</ref>
